Powered by 
Translate
Translate
10 October 2025
Nuformix plc
("Nuformix" or the "Company")
Change of Auditor
Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, announces the appointment of Kreston Reeves Audit LLP ("Kreston Reeves Audit") as auditor to the Company. The appointment of Kreston Reeves Audit follows a restructuring of the audit practice of Kreston Reeves LLP, the Company's former auditor, and will be subject to approval by shareholders at the next Annual General Meeting of the Company.
Enquiries:
|
Nuformix plc |
|
|
Dr Dan Gooding, Executive Director
|
Via IFC Advisory
|
|
CMC Markets |
|
|
Douglas Crippen |
+44 (0) 20 3003 8632 |
|
|
|
|
IFC Advisory Limited |
|
|
Tim Metcalfe Zach Cohen |
+44 (0) 20 3934 6630 nuformix@investor-focus.co.uk |
About Nuformix
Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Nuformix has a pipeline of preclinical assets with potential for significant value and early licensing opportunities.
